Helping mothers and babies, from conception to birth
At Ferring, we are committed to helping people become parents and to keeping mothers and babies healthy, from conception to birth. Over one third of our research and development investment goes towards finding innovative treatments in reproductive medicine and maternal health. We are also passionate about making a difference to people’s health and quality of life through our work in gastroenterology and urology.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
Join us
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With approximately 6,500 employees in 56 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years.
News
Ferring appoints Mirjam Mol-Arts to Executive Committee
-Ferring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
Ferring Pharmaceuticals successfully launches its inaugural Swiss Franc Bond offering for an amount of CHF 270 million
-Ferring Pharmaceuticals announced the successful launch of its inaugural Swiss Franc Bond offering for a benchmark amount of CHF 270 million. This inaugural senior unsecured bond transaction issued by Ferring Holding SA has a fixed coupon rate of 1.05% per annum.
Ferring and Igenomix collaborate to advance care in reproductive medicine and maternal health
-Ferring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.